ERBB2 and obesity disorder: A recent meta-study on the cardiotoxicity of anthracyclines (Nesser et al., 2009) showed that overweight and obesity were significantly associated with the risk of cardiotoxicity with anthracyclines and anti-Her-2 targeted therapy, consistent with the increased risk of higher body mass index in patients receiving anthracyclines and anthracyclines followed by trastuzumab in this study.